Skip to main content

Table 1 Characteristics of included studies

From: Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis

Study type Case report Cohort prospective
Studies Franz 2006 Wienecke 2006 Birca 2010 Lam 2010 Krueger 2010 Dabora 2011 Lopez 2011 Davies 2011
na 3 1 1 1 28 36 17 10
Sex M 1 1   1 17 10 8 NS
F 2   1   11 26 9
Age range (years) 14.5 – 21 19 8 9 3 – 34 19 – 60 >10 NS
Genotype TSC1      4    
TSC2 3 1 1 1 10 14   
Unknown      14 22 17 10
Rapamycin Dose (mg/day) 2 – 7 0.5 1 5 – 7 3b 2 – 6 1 0.5c
Trough (ng/ml) 7.7 – 10.9 4 – 5 3.3 – 4.5 10 – 15 5 – 15 3 – 15 4 – 8d 3 – 6
  1. NS Not specified
  2. aNumber of patients included in the analyses
  3. bmg/m2
  4. cmg/m2/day
  5. dng/dl